Skip to main content
. 2014 Feb 28;9(2):e89895. doi: 10.1371/journal.pone.0089895

Figure 4. Intraperitoneal administration of 2.17-mAlb.

Figure 4

(A) High-dose intraperitoneal administration of 2.17-mAlb accelerated weight gain (n = 10 per group, P<0.05 high-dose 2.17-mAlb compared to PBS and low-dose 2.17-mAlb. No significance between low-dose 2.17-mAlb and PBS). (B) High-dose 2.17-mAlb increased food intake (n = 10 per group, P<0.05 high-dose 2.17-mAlb compared to PBS and low-dose 2.17-mAlb. No significance between low-dose 2.17-mAlb and PBS). (C) Biomarkers in serum (n = 10 per group. Bars not connected by same letter are significantly different. (D) Tumor weight (n = 10 per group). Data are means±SD.